Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06392386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis
Lead sponsor
argenx
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 28, 2024
Completion date
September 30, 2027
Enrollment
12 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis